tetano
Editor, Senior Moderator
Sci Rep
. 2023 Sep 5;13(1):14650.
doi: 10.1038/s41598-023-41850-7. A wild boar cathelicidin peptide derivative inhibits severe acute respiratory syndrome coronavirus-2 and its drifted variants
Troy von Beck[SUP] 1 [/SUP], Karla Navarrete[SUP] 1 [/SUP], Nicholas A Arce[SUP] 2 [/SUP], Mu Gao[SUP] 3 [/SUP], Gordon A Dale[SUP] 1 [/SUP], Meredith E Davis-Gardner[SUP] 1 [/SUP], Katharine Floyd[SUP] 1 [/SUP], Luis Mena Hernandez[SUP] 1 [/SUP], Nikita Mullick[SUP] 1 [/SUP], Abigail Vanderheiden[SUP] 1 [/SUP], Ioanna Skountzou[SUP] 1 [/SUP], Suresh V Kuchipudi[SUP] 4 [/SUP], Rathi Saravanan[SUP] 5 [/SUP], Renhao Li[SUP] 2 [/SUP], Jeffrey Skolnick[SUP] 3 [/SUP], Mehul S Suthar[SUP] 1 6 [/SUP], Joshy Jacob[SUP] 7 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a clear threat to humanity. It has infected over 200 million and killed 4 million people worldwide, and infections continue with no end in sight. To control the pandemic, multiple effective vaccines have been developed, and global vaccinations are in progress. However, the virus continues to mutate. Even when full vaccine coverage is achieved, vaccine-resistant mutants will likely emerge, thus requiring new annual vaccines against drifted variants analogous to influenza. A complimentary solution to this problem could be developing antiviral drugs that inhibit SARS CoV-2 and its drifted variants. Host defense peptides represent a potential source for such an antiviral as they possess broad antimicrobial activity and significant diversity across species. We screened the cathelicidin family of peptides from 16 different species for antiviral activity and identified a wild boar peptide derivative that inhibits SARS CoV-2. This peptide, which we named Yongshi and means warrior in Mandarin, acts as a viral entry inhibitor. Following the binding of SARS-CoV-2 to its receptor, the spike protein is cleaved, and heptad repeats 1 and 2 multimerize to form the fusion complex that enables the virion to enter the cell. A deep learning-based protein sequence comparison algorithm and molecular modeling suggest that Yongshi acts as a mimetic to the heptad repeats of the virus, thereby disrupting the fusion process. Experimental data confirm the binding of Yongshi to the heptad repeat 1 with a fourfold higher affinity than heptad repeat 2 of SARS-CoV-2. Yongshi also binds to the heptad repeat 1 of SARS-CoV-1 and MERS-CoV. Interestingly, it inhibits all drifted variants of SARS CoV-2 that we tested, including the alpha, beta, gamma, delta, kappa and omicron variants.
. 2023 Sep 5;13(1):14650.
doi: 10.1038/s41598-023-41850-7. A wild boar cathelicidin peptide derivative inhibits severe acute respiratory syndrome coronavirus-2 and its drifted variants
Troy von Beck[SUP] 1 [/SUP], Karla Navarrete[SUP] 1 [/SUP], Nicholas A Arce[SUP] 2 [/SUP], Mu Gao[SUP] 3 [/SUP], Gordon A Dale[SUP] 1 [/SUP], Meredith E Davis-Gardner[SUP] 1 [/SUP], Katharine Floyd[SUP] 1 [/SUP], Luis Mena Hernandez[SUP] 1 [/SUP], Nikita Mullick[SUP] 1 [/SUP], Abigail Vanderheiden[SUP] 1 [/SUP], Ioanna Skountzou[SUP] 1 [/SUP], Suresh V Kuchipudi[SUP] 4 [/SUP], Rathi Saravanan[SUP] 5 [/SUP], Renhao Li[SUP] 2 [/SUP], Jeffrey Skolnick[SUP] 3 [/SUP], Mehul S Suthar[SUP] 1 6 [/SUP], Joshy Jacob[SUP] 7 [/SUP]
Affiliations
- PMID: 37670110
- DOI: 10.1038/s41598-023-41850-7
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a clear threat to humanity. It has infected over 200 million and killed 4 million people worldwide, and infections continue with no end in sight. To control the pandemic, multiple effective vaccines have been developed, and global vaccinations are in progress. However, the virus continues to mutate. Even when full vaccine coverage is achieved, vaccine-resistant mutants will likely emerge, thus requiring new annual vaccines against drifted variants analogous to influenza. A complimentary solution to this problem could be developing antiviral drugs that inhibit SARS CoV-2 and its drifted variants. Host defense peptides represent a potential source for such an antiviral as they possess broad antimicrobial activity and significant diversity across species. We screened the cathelicidin family of peptides from 16 different species for antiviral activity and identified a wild boar peptide derivative that inhibits SARS CoV-2. This peptide, which we named Yongshi and means warrior in Mandarin, acts as a viral entry inhibitor. Following the binding of SARS-CoV-2 to its receptor, the spike protein is cleaved, and heptad repeats 1 and 2 multimerize to form the fusion complex that enables the virion to enter the cell. A deep learning-based protein sequence comparison algorithm and molecular modeling suggest that Yongshi acts as a mimetic to the heptad repeats of the virus, thereby disrupting the fusion process. Experimental data confirm the binding of Yongshi to the heptad repeat 1 with a fourfold higher affinity than heptad repeat 2 of SARS-CoV-2. Yongshi also binds to the heptad repeat 1 of SARS-CoV-1 and MERS-CoV. Interestingly, it inhibits all drifted variants of SARS CoV-2 that we tested, including the alpha, beta, gamma, delta, kappa and omicron variants.